Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) CEO Richard J. Hawkins bought 2,214 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average cost of $8.84 per share, with a total value of $19,571.76. Following the purchase, the chief executive officer now directly owns 4,261 shares in the company, valued at approximately $37,667.24. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Lumos Pharma Trading Up 0.9 %
Shares of NASDAQ LUMO traded up $0.08 on Friday, reaching $9.00. 10,536 shares of the company traded hands, compared to its average volume of 16,147. The company has a 50 day moving average of $8.35 and a 200 day moving average of $8.29. Lumos Pharma, Inc. has a fifty-two week low of $6.15 and a fifty-two week high of $10.73.
Get Lumos Pharma alerts:Lumos Pharma (NASDAQ:LUMO – Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.98) by $0.04. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.11 million. As a group, equities analysts predict that Lumos Pharma, Inc. will post -3.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Oppenheimer assumed coverage on shares of Lumos Pharma in a research note on Tuesday, July 19th. They set an "outperform" rating and a $20.00 price objective for the company. Roth Capital reaffirmed a "buy" rating on shares of Lumos Pharma in a research note on Tuesday, August 9th.Hedge Funds Weigh In On Lumos Pharma
Institutional investors and hedge funds have recently bought and sold shares of the stock. Urban Wealth Management LLC purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $27,000. Envestnet Asset Management Inc. purchased a new position in shares of Lumos Pharma during the 4th quarter valued at approximately $72,000. Key Financial Inc purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $84,000. Opaleye Management Inc. purchased a new position in shares of Lumos Pharma during the 2nd quarter valued at approximately $166,000. Finally, Private Advisor Group LLC purchased a new position in shares of Lumos Pharma during the 1st quarter valued at approximately $263,000. Hedge funds and other institutional investors own 28.36% of the company's stock.
About Lumos Pharma
(Get Rating)
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
Read More
- Get a free copy of the StockNews.com research report on Lumos Pharma (LUMO)
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.